
    
      Researchers will perform an open label randomized clinical trial of anakinra (recombinant
      IL-1 receptor antagonist, Kineret, SOBI, Sweden) given for 4 weeks in 28 patients with
      cardiac sarcoidosis (defined using Heart Rhythm Society diagnostic criteria).
    
  